To reach the next value inflection
LicenseRx asset brief
A Novel Blood Marker for Prognostication and Treatment of Non-Small Cell Lung Cancer
Probability of Success
14% · grade C · Medium data confidence
Model PoS 14% (grade C, medium data confidence). Strongest signals: Indication pull, Modality feasibility. Biggest drag: Translational evidence.
Data maturity (22%)
36
Early / Discovery; limited public evidence of validation.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
80
Diagnostic/biomarker -- can monetize via service before full approval.
Indication pull (14%)
82
Oncology -- active buyer appetite.
Competitive whitespace (12%)
72
Under-served segment; crowded oncology field.
Translational evidence (12%)
46
No translational evidence keywords in the public summary -- lab-stage claim.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →